These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35596071)

  • 41. [Causal treatment of Alzheimer's disease: amyloid antibodies].
    Pawlowski M; Warnecke T
    Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. J&J's billion dollar punt on anti-amyloid antibody.
    Sheridan C
    Nat Biotechnol; 2009 Aug; 27(8):679-81. PubMed ID: 19668155
    [No Abstract]   [Full Text] [Related]  

  • 43. Ownership and Interoperability Challenges of Alzheimer Monoclonal Antibody Registries.
    Socal MP; Odouard IC; Kharrazi H
    JAMA Neurol; 2024 Feb; 81(2):109-110. PubMed ID: 38079170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.
    Morales-Corraliza J; Schmidt SD; Mazzella MJ; Berger JD; Wilson DA; Wesson DW; Jucker M; Levy E; Nixon RA; Mathews PM
    Neurobiol Aging; 2013 Jan; 34(1):137-45. PubMed ID: 22608241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain.
    Hatami A; Albay R; Monjazeb S; Milton S; Glabe C
    J Biol Chem; 2014 Nov; 289(46):32131-32143. PubMed ID: 25281743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. COVID-19 Timeline: Centers for Medicare and Medicaid Services (CMS) Changes and Primary Care Support Were Not Enough to Prevent Practice Losses.
    Gausvik C; Jabbarpour Y
    J Am Board Fam Med; 2021 Feb; 34(Suppl):S7-S9. PubMed ID: 33622808
    [No Abstract]   [Full Text] [Related]  

  • 48. Recent advance in immunotherapies for Alzheimer disease: with special reference to DNA vaccination.
    Okura Y; Matsumoto Y
    Hum Vaccin; 2009 Jun; 5(6):373-80. PubMed ID: 19221518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The problematic lag between FDA approval of medical devices and CMS coverage.
    Knight BP; Deering TF; Gold MR; Mittal S; Singh JP
    J Cardiovasc Electrophysiol; 2021 Jul; 32(7):1801-1802. PubMed ID: 34056780
    [No Abstract]   [Full Text] [Related]  

  • 50. Bariatric surgery complications before vs after implementation of a national policy restricting coverage to centers of excellence.
    Dimick JB; Nicholas LH; Ryan AM; Thumma JR; Birkmeyer JD
    JAMA; 2013 Feb; 309(8):792-9. PubMed ID: 23443442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bapineuzumab in Alzheimer's disease: where now?
    Wilcock GK
    Lancet Neurol; 2010 Feb; 9(2):134-6. PubMed ID: 20129159
    [No Abstract]   [Full Text] [Related]  

  • 52. Doubts persist for claimed Alzheimer's drug.
    Servick K
    Science; 2019 Dec; 366(6471):1298. PubMed ID: 31831649
    [No Abstract]   [Full Text] [Related]  

  • 53. Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease.
    Spillantini MG; Goedert M; Jakes R; Klug A
    Proc Natl Acad Sci U S A; 1990 May; 87(10):3947-51. PubMed ID: 2111023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology.
    Solomon B; Frenkel D
    J Neural Transm Suppl; 2002; (62):321-5. PubMed ID: 12456075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unfairness to Patients With Alzheimer Disease in Medicare's Coverage of Antiamyloid Immunotherapy.
    Stern AM; Selkoe DJ
    JAMA Neurol; 2022 Oct; 79(10):962-963. PubMed ID: 35913706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Application of Anti-β-Amyloid Monoclonal Antibodies: Untangling Eligibility.
    Howe MD; Rabinovici GD; Salloway SP
    Neurology; 2023 Nov; 101(19):811-812. PubMed ID: 37586880
    [No Abstract]   [Full Text] [Related]  

  • 57. It's a zoo out there... we're doing PET scans.
    Mulaik MW
    Radiol Manage; 2014; 36(3):42-4. PubMed ID: 25004685
    [No Abstract]   [Full Text] [Related]  

  • 58. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
    Taguchi H; Planque S; Nishiyama Y; Szabo P; Weksler ME; Friedland RP; Paul S
    Autoimmun Rev; 2008 May; 7(5):391-7. PubMed ID: 18486927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist.
    Fitz NF; Castranio EL; Carter AY; Kodali R; Lefterov I; Koldamova R
    J Alzheimers Dis; 2014; 41(2):535-49. PubMed ID: 24643138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coding and Reimbursement for Vestibular Tests by the U.S. Centers for Medicare and Medicaid Services (CMS).
    Fife TD; Desmond AL; Kerber KA
    Otol Neurotol; 2021 Dec; 42(10):e1544-e1547. PubMed ID: 34766950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.